These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16846404)

  • 1. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes?
    Goldstein BJ
    Int J Clin Pract; 2006 Jul; 60(7):873-83. PubMed ID: 16846404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
    Bhansali A; Modi P
    J Indian Med Assoc; 2005 Jun; 103(6):343-6. PubMed ID: 16225162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ; White RD
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes.
    Kahn SE; Zinman B
    Diabetes Care; 2007 Jun; 30(6):1672-6. PubMed ID: 17351271
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflecting on type 2 diabetes prevention: more questions than answers!
    Rosenstock J
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.
    Guerrero-Romero F; Rodríguez-Morán M
    Eur J Clin Invest; 2006 Nov; 36(11):796-802. PubMed ID: 17032347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feature selection and classification model construction on type 2 diabetic patients' data.
    Huang Y; McCullagh P; Black N; Harper R
    Artif Intell Med; 2007 Nov; 41(3):251-62. PubMed ID: 17707617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.